<DOC>
	<DOCNO>NCT01767714</DOCNO>
	<brief_summary>The study determine NHL patient mobilize G-CSF ( 10 µg/kg/day [ GRAN® ] ) plus 0.24 mg/kg/day plerixafor likely achieve target number ≥5 × 10^6 CD34+ cells/kg 4 few day apheresis NHL patient mobilize G-CSF plus placebo .</brief_summary>
	<brief_title>Evaluation Plerixafor Plus G-CSF Mobilize Collect 5×10^6CD34+ Cells/kg Non-Hodgkin 's Lymphoma ( NHL ) Patients Autologous Transplantation</brief_title>
	<detailed_description>Eligible patient unable achieve adequate apheresis cell count may enter Open-Label Rescue Period receive plerixafor , follow study schedule Double-Blind Treatment Period .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>JM 3100</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Has biopsyconfirmed diagnosis NHL Is first second complete remission partial remission , define purpose study complete partial response follow first secondline therapy Treatment autologous peripheral HSC transplant plan patient eligible autologous transplantation Has Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 Has recover acute toxic effect prior chemotherapy cancer treatment . Has actual body weight &lt; 175 % ideal body weight ( IBW ) The patient agree use highly effective method contraception Day 1 ≥3 month follow plerixafor treatment . Concurrent serious illness pathological condition Has undergone previous HSC collection collection attempt Has autologous allogeneic HSC transplant Has active central nervous system ( CNS ) involvement Bone marrow lymphoma cell involvement &gt; 20 % , assess bone marrow biopsy within 4 month sign ICF Has receive radiation therapy pelvis Has diagnosis leukemia include type CLL Active infection Pregnant nursing Anticipated posttransplant chemotherapy and/or radiation therapy diaphragm Received prior radioimmunotherapy Prior 1,3bis ( 2chloroethyl ) 1nitrosourea ( BCNU ) within 6 week prior first dose GCSF Prior cancer therapy , investigational therapy within 4 week prior first dose GCSF Prior granulocyte/macrophagecolony stimulate factor ( GMCSF ) pegfilgrastim within 3 week prior first dose GCSF Prior GCSF within 2 week prior first dose GCSF Inadequate organ funtion evidence unacceptable laboratory result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>hematopoietic stem cell transplantation</keyword>
</DOC>